<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">This success was not the end of the story in the battle against HIV, as resistance to anti-HIV drugs emerges, often rapidly. To combat this, new agents in existing classes and new classes of drugs from both more serendipitous screening and rational design have been developed. Twenty-four anti-HIV drugs have received regulatory approval: eleven are targeted at the HIV reverse transcriptase and ten are targeted at the HIV protease, the others target HIV cell entry, HIV cell fusion and HIV integrase (
 <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/nrd/journal/v6/n12/suppinfo/nrd2485.html" xmlns:xlink="http://www.w3.org/1999/xlink">Supplementary information S1</ext-link> (table); available online).
</p>
